Global /Singapore /Healthcare /Biotechnology /8YY

Embracing Future Holdings Ltd.

8YY

• SGX: 8YY • Delayed

0.0510SGD 0%

0.0396 USD

As of 13 June 2026, Embracing Future Holdings Ltd. has a market cap of $68.77M USD, ranking #28235 globally and #313 in Singapore. It ranks #2552 in the Healthcare sector, and #493 in the Biotechnology industry.

Global Rank

28235

Country Rank

313

Sector Rank

2552

Industry Rank

493

Key Stats

Market Cap

$68.77MUSD

88.41M SGD

Enterprise Value

$70.14MUSD

90.25M SGD

Revenue (TTM)

$4.09MUSD

5.26M SGD

EBITDA (TTM)

-$2.9MUSD

-3.73M SGD

Net Income (TTM)

-$3.08MUSD

-3.96M SGD

EBITDA Margin

-71%

Profit Margin

-75%

PS Ratio

16.8

PB Ratio

58.5

Company Profile

Country (HQ)

Singapore

Sector

Healthcare

Industry

Biotechnology

Employees

Founded

2009

Website

ebfholdings.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-7.3%	2%	-37%	113%	-1.9%	155%	183%	-82%

News

Markets

Exchange	Ticker	Price	Quotes
Singapore Exchange (SGX) MIC: XSES PRIMARY	8YY Biolidics Ltd Ordinary Shares ISIN: SGXE89830751 Shares Out.: Shares Outstanding: 1.733B¹ Shares Float: 552.771M² TV: TradingView: SGX: 8YY SA: Stock Analysis: SGX: 8YY YF: Yahoo Finance: 8YY.SI GF: Google Finance: SGX: 8YY BA: Barron's: 8YY MS: Morningstar: XSES: 8YY	0.0510 SGD	TV: TradingView: SGX: 8YY SA: Stock Analysis: SGX: 8YY YF: Yahoo Finance: 8YY.SI GF: Google Finance: SGX: 8YY BA: Barron's: 8YY MS: Morningstar: XSES: 8YY

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Embracing Future Holdings Ltd.

Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.

Similar Companies

Industry: Biotechnology (Singapore)

Name	Market Cap (USD) diff.	PE	Country
Wave Life Sciences Ltd. NASDAQ: WVE	$1.36B 2K%	-	Singapore
Prestige BioPharma Ltd. KRX: 950210	$71.44M 108.65B KRW 3.9%	39.8	Singapore
CytoMed Therapeutics Ltd. NASDAQ: GDTC	$11.71M -83%	-	Singapore

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 265K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 232K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 69K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 65K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 61K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 61K%	37.2	Switzerland

chevron_leftBack